Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  dasatinib
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 65 for your search:
Start Over
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: NCI, Other
Protocol IDs: TOTXVI, 5R01CA140729, 5F32CA141762, R37CA036401, 5R01CA090246, Aspar PK-PD-T16, NCI-2011-01254, NCT00549848
Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 4443, 2007-006185-15, ISRCTN54923521, NCT01460693
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AMLSG 21-13, NCT02013648
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients =60 Years in Deep Molecular Response
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 60 and over
Sponsor: Other
Protocol IDs: AOBSTMO-OPTKIMA-2014, NCT02326311
A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SCLL084993, NCT00829647
Dasatinib In Combination With Trastuzumab And Paclitaxel In The First Line Treatment Of Her2-Positive Metastatic Breast Cancer (MBC) Patients
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GEICAM/2010-04, NCT01306942
Phase I/II - Dasatinib and Decitabine
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011-0333, CA180357, NCI-2012-00014, NCT01498445
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PRI-724-201, NCT01606579
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2011-203, NCT01609816
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2011-204, NCT01643603
Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2012-0697, NCI-2013-00551, NCT01751425
Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI, Other
Protocol IDs: 12393, NCI-2013-01141, NCT01876953
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000598300, E2607, ECOG-E2607, NCT00700882
A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0809009979, NCT00918463
Evaluation of Response of Dasatinib to Treat Mastocytosis
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: CA 180-287, NCT00979160
Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: D'Accord study, NCT01051115
Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: DASA-TRAS, NCT01310010
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2008-0598, NCI-2011-00861, NCT01319981
A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 20 and over
Sponsor: Other
Protocol IDs: KCSG-02, NCT01342679
A Study of Dasatinib in Chronic Lymphocytic Leukemia in Patients Who Exhibit in Vitro Dasatinib Sensitivity
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: OHSU-6146, NCI-2011-03136, HEM 10010-L, NCT01441882
Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 25
Sponsor: Other
Protocol IDs: RIST-rNB-2011, NCT01467986
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-034, CA180264, NCT01488318
Phase IIb Study of Dasatinib Versus Imatinib in Patients With CML-CP Who Have Not Achieved an Early Optimal Response to Imatinib
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-399, 2011-006181-41, NCT01593254
Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 to 69
Sponsor: NCI, Other
Protocol IDs: IRB00007195, 1R21CA159265-01, NCT01620216
Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial
Phase: Phase II
Type: Treatment
Status: Active
Age: 15 and over
Sponsor: Other
Protocol IDs: SHSG-01, NCT01627132
Start Over